In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


World View

Approximately 25% of active drug development originates from China, with a focus on biologics, cell therapies, and cancer R&D. Despite strong interest from multinational pharmaceutical companies, a financing crunch in the startup space is impacting China's biotech sector.

Latin America And Caribbean Move Towards Creating A New Regional Regulator

Industry support for a new regional regulator for Latin America and the Caribbean is cautious and experts warn that it could harm competitiveness of the region.

The Growing Pains Of Chinese Biotech

The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.

How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing

An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.

How The UK Is Reinvigorating Its Clinical Trials Industry

In the year since the Association of the British Pharmaceutical Industry raised the alarm about drastically dwindling clinical trial recruitment numbers in the UK, the country has taken a number of steps to try to turn things around.

The Asia 100 ranking is based on Citeline’s analysis of fiscal year 2022 prescription sales data. For more information contact: [email protected].

See more content from Scrip Asia 100.